JP2005525355A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525355A5
JP2005525355A5 JP2003570859A JP2003570859A JP2005525355A5 JP 2005525355 A5 JP2005525355 A5 JP 2005525355A5 JP 2003570859 A JP2003570859 A JP 2003570859A JP 2003570859 A JP2003570859 A JP 2003570859A JP 2005525355 A5 JP2005525355 A5 JP 2005525355A5
Authority
JP
Japan
Prior art keywords
composition according
amount
composition
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003570859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525355A (ja
JP4480400B2 (ja
Filing date
Publication date
Priority claimed from GB0204712A external-priority patent/GB2386066A/en
Application filed filed Critical
Publication of JP2005525355A publication Critical patent/JP2005525355A/ja
Publication of JP2005525355A5 publication Critical patent/JP2005525355A5/ja
Application granted granted Critical
Publication of JP4480400B2 publication Critical patent/JP4480400B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003570859A 2002-02-28 2003-02-12 サリチルアニリド化合物、ポリマー成分および少なくとも1種の他の抗寄生虫化合物を含む持続性駆虫組成物 Expired - Lifetime JP4480400B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0204712A GB2386066A (en) 2002-02-28 2002-02-28 Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
PCT/GB2003/000645 WO2003072113A1 (en) 2002-02-28 2003-02-12 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound

Publications (3)

Publication Number Publication Date
JP2005525355A JP2005525355A (ja) 2005-08-25
JP2005525355A5 true JP2005525355A5 (https=) 2006-04-06
JP4480400B2 JP4480400B2 (ja) 2010-06-16

Family

ID=9931978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003570859A Expired - Lifetime JP4480400B2 (ja) 2002-02-28 2003-02-12 サリチルアニリド化合物、ポリマー成分および少なくとも1種の他の抗寄生虫化合物を含む持続性駆虫組成物

Country Status (23)

Country Link
US (1) US9289380B2 (https=)
EP (1) EP1478372B1 (https=)
JP (1) JP4480400B2 (https=)
AP (1) AP1977A (https=)
AR (1) AR038852A1 (https=)
AT (1) ATE347897T1 (https=)
AU (1) AU2003205887B2 (https=)
BR (1) BR0307974B1 (https=)
CA (1) CA2476520C (https=)
CO (1) CO5611154A2 (https=)
CR (1) CR7429A (https=)
CY (1) CY1107530T1 (https=)
DE (1) DE60310377T2 (https=)
DK (1) DK1478372T3 (https=)
EC (1) ECSP045320A (https=)
ES (1) ES2275076T3 (https=)
GB (1) GB2386066A (https=)
MX (1) MXPA04007996A (https=)
NZ (1) NZ534704A (https=)
PT (1) PT1478372E (https=)
SI (1) SI1478372T1 (https=)
WO (1) WO2003072113A1 (https=)
ZA (1) ZA200406782B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002952597A0 (en) * 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE602004015755D1 (de) * 2003-03-31 2008-09-25 Alza Corp Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
US7666444B2 (en) 2004-02-02 2010-02-23 Wyeth Antiparasitic composition
WO2006061214A1 (en) * 2004-12-10 2006-06-15 Bayer Healthcare Ag Anthelmintic composition
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
FR2991173B1 (fr) 2012-06-04 2015-11-06 Virbac Composition veterinaire a administration cutanee a base d'oxyclozanide
AU2014324837B2 (en) * 2013-09-30 2019-01-17 Zoetis Services Llc Long-acting spiro-isoxazoline formulations
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
GB201604484D0 (en) * 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
DE2263509C2 (de) 1972-12-27 1981-12-24 Rudolf Dr. 6380 Bad Homburg Kürner Deodorant
US4005218A (en) 1975-03-18 1977-01-25 Janssen Pharmaceutica N.V. Antiparasitic salicylanilide derivatives
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4206205A (en) 1977-10-03 1980-06-03 Merck & Co., Inc. Monosaccharide and aglycone derivatives of C-076
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4171314A (en) 1977-12-19 1979-10-16 Merck & Co., Inc. 13-Halo and 13-deoxy C-076 compounds
US4173571A (en) 1977-12-19 1979-11-06 Merck & Co., Inc. 13-Halo and 13-deoxy derivatives of C-076 compounds
US4128632A (en) 1978-02-13 1978-12-05 Merck & Co., Inc. Solubilization of Rafoxanide
NZ197796A (en) 1980-08-04 1984-11-09 Merck & Co Inc Stabilised aqueous formulations containing ivermectin
NZ210505A (en) 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
NZ223200A (en) * 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
US5273805A (en) * 1991-08-05 1993-12-28 Minnesota Mining And Manufacturing Company Structured flexible carrier web with recess areas bearing a layer of silicone on predetermined surfaces
NZ335166A (en) 1999-04-14 2001-11-30 Ashmont Holdings Ltd Anthelmintic composition containing triclabendazole in at least one solvent
CN1054504C (zh) 1993-03-15 2000-07-19 科尔加特·帕尔莫利弗公司 洁牙剂
PL174488B1 (pl) 1993-05-10 1998-08-31 Merck & Co Inc Preparat do zwalczania pasożytów zwierząt oraz sposób wytwarzania preparatu do zwalczania pasożytów zwierząt
DE69432985D1 (de) 1993-06-15 2003-09-04 Australian Nat University Acto Synergistische anthelmintische zusammensetzungen gegen fasciola hepatica und andere fascola spezien
NZ248486A (en) * 1993-08-24 1996-07-26 Ashmont Holdings Limited Subst Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent
WO1995016447A1 (en) 1993-12-13 1995-06-22 Michael Hilary Burke Anthelmintic composition containing rafoxanide and fenbendazole
FR2739778B1 (fr) 1995-10-13 1997-12-12 Virbac Lab Formulation topique destinee a traiter la maladie de la douve du foie chez l'animal
US5773422A (en) * 1996-01-29 1998-06-30 Komer; Gene Avermectin formulation
US6193989B1 (en) 1997-03-21 2001-02-27 Biogenesis S.A. Long acting injectable parasiticidal composition and the process for its preparation
US6340672B1 (en) 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation
AUPQ875700A0 (en) * 2000-07-13 2000-08-03 Reflex Research Limited Combination compositions
AUPR510001A0 (en) 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method

Similar Documents

Publication Publication Date Title
JP2005525355A5 (https=)
EP1713450B1 (en) Rapidly dissolving film for delivery of an active agent
WO2005000265A3 (en) Gel-stabilized nanoparticulate active agent compositions
WO2001085143A3 (fr) Compositions pharmaceutiques pour administration transdermique d' agents anti-inflammatoires
CA2594215A1 (en) Sustained-release nanoparticle compositions and methods for using the same
EP1669364A3 (en) Methods and compositions for treating hepatitis C virus
JP2002226399A5 (https=)
RU2002135623A (ru) Рецептура на основе гепарина, глюкозаминогликана или гепариноида и применение рецептуры и ее основы
PT1210934E (pt) Preparação de transportador farmacêutico aplicável a superfícies de mucosas
JP2005524730A5 (https=)
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
NO20011639L (no) Bionedbrytbare triblokk-kopolymerer av polyester- polyetylenglykol med lav molekylvekt og med reversible termiskegelingsegenskaper
JP2007524645A5 (https=)
CO5611154A2 (es) Composicion antiparasitaria de accion prolongada que contienen un compuesto de salicilanilida, una especie polimerica y por lo menos otro compuesto antiparasitario
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
PT910339E (pt) Aerossol polar bucal
TR200101088T2 (tr) Sürekli salınımlı farmasötik kompozisyon ve farmasötik olarak aktif ajanın salınma metodu
JP2002544214A5 (https=)
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
DK1441769T3 (da) Farmaceutiske formuleringer, der indeholder lave koncentrationer af peroxid, til behandling eller forebyggelse af vaginale infektioner
WO2005107773A8 (en) Solid dosage form of wetted heparin
WO2002028362A3 (fr) Composition vaccinale et procede de stabilisation
CA2434785A1 (en) Polymer compositions comprising telomers and articles or parts using these compositions
EA200600237A1 (ru) Антипаразитарная композиция
JP2003160735A5 (https=)